Skip to main content

Table 4 Vaccine trials including checkpoint inhibitor mABs

From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

NCT Number Title Indication Sponsor/Collaborators Phases Vaccine Type Vaccine Name MAB
NCT00077532 (completed) Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma Melanoma National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) Phase 2 Peptide-based vaccine (adjuvanted) gp100 antigen in incomplete Freund’s adjuvant Ipilimumab
NCT00094653 (completed) MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Melanoma Bristol-Myers Squibb Phase 3 Peptide-based vaccine (multi-peptide) MDX-1379 (gp100) Melanoma Peptide Vaccine Ipilimumab
NCT00084656 (completed) Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Melanoma Bristol-Myers Squibb National Cancer Institute (NCI) Phase 2 Peptide-based vaccine (multi-peptide, adjuvanted) Tyrosinase/gp100/MART-1 Peptide vaccine in Montanide Ipilimumab
NCT01067287 (ongoing) Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation Myeloma Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Brigham and Women's Hospital Rambam Health Care Campus Gateway for Cancer Research Department of Defense Phase 2 Dendritic cell-based vaccine (autologous tumour-fused) Dendritic Cell/Myeloma Fusion Cell Vaccine with or without CT-011 Pidilizumab (CT-011)
NCT02054520 (ongoing) Immunotherapy Study for Patients With Stage IV Melanoma Melanoma NewLink Genetics Corporation Phase 2 Tumour cell-based vaccine (allogenic, aGal transfected) Hyperacute Melanoma Cancer vaccine Dorgenmeltucel-L Ipilimumab
NCT01096602 (ongoing) Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission Leukemia Beth Israel Deaconess Medical Center National Institutes of Health (NIH) CureTech Ltd Dana-Farber Cancer Institute Phase 2 Dendritic cell-based vaccine (autologous tumour-fused) Dendritic Cell/AML Fusion Cell Vaccine with or without CT-011 Pidilizumab (CT-011)
NCT01441765 (ongoing) PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine Renal Cell Cancer (RCC) Beth Israel Deaconess Medical Center National Institutes of Health (NIH) National Cancer Institute (NCI) Dana-Farber Cancer Institute Phase 2 Dendritic cell-based vaccine (autologous tumour-fused) Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine with or without CT-011 Pidilizumab (CT-011)
NCT01420965 (ongoing) Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Neoplasm Georgia Regents University Phase 2 Dendritic cell-based vaccine (autologous tumour-pulsed) Provenge (Sipuleucel-T/APC8015) + Drug: CT-011 (Anti-PD1 Antibody) Pidilizumab (CT-011)
NCT01896869 (ongoing) A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center Phase 2 Tumour cell-based vaccine (allogenic, GM-CSF transfected) GVAX Ipilimumab
NCT02243371 (ongoing) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center Bristol-Myers Squibb Stand Up To Cancer Aduro BioTech AACR Research Acceleration Network Phase 2 Tumour cell-based vaccine (allogenic, GM-CSF transfected), Bacteria-based vaccine (Listeria) GVAX nivolumab
NCT00032045 (completed) Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Melanoma National Cancer Institute (NCI) Phase 2 Peptide-based vaccine (adjuvanted) gp100 antigen incomplete Freund’s adjuvant Ipilimumab
NCT00357461 (withdrawn prior to enrolment) Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma Melanoma Bristol-Myers Squibb National Cancer Institute (NCI) Phase 2 Peptide-based vaccine (multi-peptide, adjuvanted) gp100:209-217(210M) & gp100:280-288(288V) peptide vaccine in incomplete Freund’s adjuvant Ipilimumab